Navigation Links
Verenium Announces Proposed Public Offering of Common Stock
Date:10/5/2009

CAMBRIDGE, Mass., Oct. 5 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNMD), a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, today announced that it intends to offer, subject to market, regulatory and other conditions, shares of its common stock, and potentially warrants, in an underwritten public offering. The offering is expected to price before 9:30 am EDT on Tuesday, October 6, 2009. Lazard Capital Markets LLC is acting as the sole book-running manager for the offering.

The securities described above are being offered by the Company pursuant to a shelf registration statement which was filed with the Securities and Exchange Commission (SEC) and became effective on January 14, 2008. A prospectus supplement describing the terms of this offering will be filed with the SEC and forms part of the effective Registration Statement.

When available, copies of the final prospectus supplement and accompanying base prospectus relating to this offering can be obtained at the SEC's website at http://www.sec.gov or from Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY 10020.

This press release is not an offer to sell or the solicitation of an offer to buy these securities, nor shall it constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Verenium

Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and animal health markets. The Company possesses integrated, end-to-end capabilities and cutting-edge technology in pre-treatment, novel enzyme development, fermentation and project development for next-generation biofuels. Through Vercipia, the Company is moving rapidly to commercialize cellulosic technology for the production of ethanol from a wide array of non-food feedstocks, including dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars.

Verenium's Specialty Enzyme business harnesses the power of enzymes to create a broad range of specialty products to meet high-value commercial needs. Verenium's world class R&D organization is renowned for its capabilities in the rapid screening, identification, and expression of enzymes-proteins that act as the catalysts of biochemical reactions. For more information on Verenium, visit http://www.verenium.com.

Forward Looking Statements

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to the Company's expectations regarding its fund raising efforts, including the closing of the current public offering, its financial condition, operations, capabilities, commercialization activities, and future financial performance, results and objectives, all of which are prospective. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with the costs, labor requirements and labor availability associated with operating its business, including ethanol production, and risks and other uncertainties more fully described in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's annual report on Form 10-K for the year ended December 31, 2008 and any updates contained in its subsequently filed quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any intent or obligation to update these forward-looking statements.

    Contacts:

    Kelly Lindenboom                  Sarah Carmody
    Vice President, Corporate         Sr. Corporate Communications Associate
    Communications
    617-674-5335                      617-674-5357
    kelly.lindenboom@verenium.com     sarah.carmody@verenium.com

SOURCE Verenium Corporation


'/>"/>
SOURCE Verenium Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
2. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
3. Verenium Corporation to Present at the Pacific Growth Equities 2007 Clean Technology & Industrial Growth Conference
4. Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy
5. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
6. Verenium Reports Financial Results for the First Quarter 2008
7. Verenium Appoints John F. Dee to Board of Directors
8. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
9. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
10. Verenium Corporation to Announce Third Quarter 2008 Financial Results
11. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... Lajollacooks4u welcomed the San ... The organization, a worldwide society of professional women with high achievement in the fields ... annual dinner. , Twelve members began with an olive oil tasting to ...
(Date:9/20/2017)... ... September 20, 2017 , ... Diversity focused business accelerator, ... Fueling the Growth pitch competition to uncover the top technology-driven, women-led startups in Boston, ... integral part of each city’s entrepreneurial events going on that week – in Boston, ...
(Date:9/20/2017)... Worth, Texas (PRWEB) , ... September 20, 2017 , ... ... stem cell therapy succeeded after standard medicine failed. Many of these people had lost ... Progress, Not Regression Free Download (pdf) , “Neil takes ...
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of this educational ... fume hood. Along with the advantages and disadvantages of ductless, filtered fume hoods, ... in the laboratory. , Attendees will learn from an industry expert about the ...
Breaking Biology Technology:
(Date:8/23/2017)... 23, 2017  The general public,s help is being enlisted in what,s ... live in and on the human body –and are believed to affect ... The Microbiome Immunity Project is ... starting with the gut. The project's goal is to help advance scientific ... ...
(Date:8/15/2017)... 15 2017   ivWatch LLC , a medical device company ... today announced receipt of its ISO 13485 Certification, the global standard ... Organization for Standardization (ISO®). ... Model 400 Continuous Monitoring device for the early detection of IV ... "This is an important milestone for ...
(Date:7/20/2017)... 2017 Delta (NYSE: DAL ) customers now can ... at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan ... Delta,s biometric boarding pass experience that ... now integrated into the boarding process to allow eligible Delta SkyMiles Members ...
Breaking Biology News(10 mins):